HROW
What one share of Harrow holds
Pharmaceutical Preparations
We help U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription
Harrow’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.40 |
|---|---|
| Profit | −$1.00 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | $0.13 |
| Cash and investments | $2.24 |
| Debt | $7.80 |
| Book value | $0.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.56 | −$1.50 | $0.54 | −$1.42 | — | $0.35 |
| 2017 | $1.34 | −$0.60 | $0.04 | −$0.48 | — | $0.13 |
| 2018 | $1.74 | $0.61 | $0.07 | −$0.05 | — | $1.02 |
| 2019 | $1.93 | $0.01 | $0.06 | −$0.02 | — | $1.09 |
| 2020 | $1.89 | −$0.13 | $0.03 | −$0.08 | — | $1.06 |
| 2021 | $2.71 | −$0.69 | $0.07 | $0.12 | — | $0.42 |
| 2022 | $3.23 | −$0.51 | $0.09 | −$0.03 | — | $0.92 |
| 2023 | $3.99 | −$0.75 | $0.04 | $0.07 | — | $2.01 |
| 2024 | $5.60 | −$0.49 | $0.04 | −$0.67 | — | $1.96 |
| 2025 | $7.41 | −$0.14 | $0.02 | $1.17 | — | $1.41 |